Facts and artefacts of coagulation assays for factor Xa inhibitors

被引：12
作者：
Haas, Sylvia [1 ]
机构：
[1] Tech Univ Munich, Inst Expt Oncol & Therapy Res, Munich, Germany
来源：
THROMBOSIS AND HAEMOSTASIS | 2010年 / 103卷 / 04期
关键词：
TOTAL HIP-REPLACEMENT; TOTAL KNEE ARTHROPLASTY; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; POPULATION PHARMACOKINETICS; RIVAROXABAN; THROMBOPROPHYLAXIS; PHARMACODYNAMICS; BAY-59-7939; PREVENTION;
D O I：
10.1160/TH10-01-0080
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：686 / 688
页数：3
相关论文
共 17 条
  • [1] Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) - The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
    Agnelli, Giancarlo
    Gallus, Alexander
    Goldhaber, Samuel Z.
    Haas, Sylvia
    Huisman, Menno V.
    Hull, Russel D.
    Kakkar, Ajay K.
    Misselwitz, Frank
    Schellong, Sebastian
    [J]. CIRCULATION, 2007, 116 (02) : 180 - 187
  • [2] A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
    Buller, Harry R.
    Lensing, Anthonie W. A.
    Prins, Martin H.
    Agnelli, Giancarlo
    Cohen, Alexander
    Gallus, Alexander S.
    Misselwitz, Frank
    Raskob, Gary
    Schellong, Sebastian
    Segers, Annelise
    [J]. BLOOD, 2008, 112 (06) : 2242 - 2247
  • [3] BULLER HR, BEHALF EINSTEIN INVE
  • [4] Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
    Eriksson, Bengt I.
    Borris, Lars C.
    Friedman, Richard J.
    Haas, Sylvia
    Huisman, Menno V.
    Kakkar, Ajay K.
    Bandel, Tiemo J.
    Beckmann, Horst
    Muehlhofer, Eva
    Misselwitz, Frank
    Geerts, William
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) : 2765 - 2775
  • [5] A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
    Eriksson, Bengt I.
    Borris, Lars C.
    Dahl, Ola E.
    Haas, Sylvia
    Huisman, Menno V.
    Kakkar, Ajay K.
    Muehlhofer, Eva
    Dierig, Christoph
    Misselwitz, Frank
    Kalebo, Peter
    [J]. CIRCULATION, 2006, 114 (22) : 2374 - 2381
  • [6] Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
    Eriksson, BI
    Borris, L
    Dahl, OE
    Haas, S
    Huisman, MV
    Kakkar, AK
    Misselwitz, F
    Kälebo, P
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (01) : 121 - 128
  • [7] Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects
    Jiang, Ji
    Hu, Yufang
    Zhang, Jianyan
    Yang, Jueling
    Mueck, Wolfgang
    Kubitza, Dagmar
    Bauer, Richard J.
    Meng, Ling
    Hu, Pei
    [J]. THROMBOSIS AND HAEMOSTASIS, 2010, 103 (01) : 234 - 241
  • [8] Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
    Kakkar, Ajay K.
    Brenner, Benjamin
    Dahl, Ola E.
    Eriksson, Bengt I.
    Mouret, Patrick
    Muntz, Jim
    Soglian, Andrea G.
    Pap, Akos F.
    Misselwitz, Frank
    Haas, Sylvia
    [J]. LANCET, 2008, 372 (9632) : 31 - 39
  • [9] Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
    Kubitza, D
    Becka, M
    Voith, B
    Zuehlsdorf, M
    Wensing, G
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (04) : 412 - 421
  • [10] Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
    Lassen, Michael R.
    Ageno, Walter
    Borris, Lars C.
    Lieberman, Jay R.
    Rosencher, Nadia
    Bandel, Tiemo J.
    Misselwitz, Frank
    Turpie, Alexander G. G.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (26) : 2776 - 2786
12